Close

International IP and Small Businesses: Novavax CEO Testifies on BIO's Behalf

Oct 27 2011
Stanley C. Erck, President and CEO of Novavax testified at the USPTO on behalf of BIO to discuss the importance of IP protection internationally for small biotechnology companies.

Human Subject Research Protections: BIO Comments on HHS ANPRM on Human Subjects Research Protections (Common Rule)

Oct 26 2011

...

EHB: BIO Public Statement: Essential Health Benefits Listening Session

Oct 25 2011

...

Sunshine: BIO co-signs letter to HHS Secretary Kathleen Sebelius

Oct 25 2011

...

Sunshine Letter to HHS Secretary Kathleen Sebelius

Oct 25 2011
BIO signs on to letter to HHS Secretary Kathleen Sebelius, regarding the Physician Payments Sunshine Provision.

PDUFA V: BIO Supports Timely Reauthorization of PDUFA to Promote the Development of Innovative Therapies and Speed New Medicines to Patients

Oct 24 2011

...

BIO Comments on the CARB on the Harmonization Chapter

Oct 21 2011
BIO comments on the draft “Harmonization” chapter (the chapter) of CARB report.

BIO Comments on the CARB on the Harmonization Chapter

Oct 21 2011
BIO comments on the draft “Harmonization” chapter (the chapter) of CARB report.

Paraguay IP Section 306 Monitoring: BIO Comments

Oct 20 2011
BIO urges the United States Trade Representative to continue to address the persistent deficiencies in patent protection and data protection regimes in Paraguay.  These deficiencies raise issues in respect to Paraguay's bilateral and international obligations and deny adequate and effective protection for the intellectual property rights of BIO's members.

NADAC: BIO's Comments on the Survey of Retail Prices

Oct 20 2011

...